Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-4021586 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction

Next Previous
Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-4021586 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ulacamten (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms AMBER-HFpEF
  • Sponsors Cytokinetics

Most Recent Events

  • 06 May 2025 According to a Cytokinetics media release, the patient enrollment of the first two cohorts is expected to complete in 2H 2025.
  • 21 Jan 2025 Status changed to recruiting, according to a cytokinetics media release
  • 21 Jan 2025 According to a Cytokinetics media release, today announced that AMBER-HFpEF is open to enrollment in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) more than or equal to 60%.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top